Gene Delivery and Gene Editing (Focus Group - GDGE)
Lipid nanoparticles (LNPs) are a leading platform for nucleic acid delivery, but their natural liver accumulation limits extrahepatic applications. Two strategies can address this: (i) modifying lipid composition to alter biodistribution and (ii) ligand-based surface functionalization for active targeting. While lipid modifications can influence organ tropism, they often lack precision and may lead to rapid clearance.In contrast, ligand decoration provides a versatile and modular platform for targeted delivery, independent of lipid composition constraints.
Aroa Duro Castaño, PhD (she/her/hers)
R&D Director
Curapath
Paterna, Comunidad Valenciana, Spain